Claims
- 1. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5 (SEQ ID NO: 1), wherein
Xaa1 is a hydrophobic amino acid, Xaa2 is a basic amino acid, Xaa3 is a polar amino acid with a side chain comprising an amide, Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa5 is an acidic amino acid, and wherein the peptide binds to fibrinogen.
- 2. The isolated or purified peptide of claim 1, wherein the amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
- 3. The isolated or purified peptide of claim 2, wherein Xaa1 is Ala, Xaa2 is Arg, Xaa3 is Asn or Gln, and Xaa5 is Asp.
- 4. The isolated or purified peptide of claim 3, wherein the peptide consists essentially of SEQ ID NO: 20 or SEQ ID NO: 21.
- 5. A composition comprising the peptide of claim 1 and a carrier.
- 6. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Gly-Xaa6-Arg-Xaa7 (SEQ ID NO: 2), wherein
Xaa6 is Pro or Gln, and Xaa7 is any amino acid except Pro, and wherein the peptide binds to fibrinogen.
- 7. The isolated or purified peptide of claim 6, wherein Xaa6 is Pro.
- 8. The isolated or purified peptide of claim 6, wherein the peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 22-27, and 29-32.
- 9. A composition comprising the peptide of claim 6 and a carrier.
- 10. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 7-15, 17-19, and 28, wherein the peptide binds to fibrinogen.
- 11. The isolated or purified peptide of claim 11, wherein the amino acid sequence is selected from the group consisting of SEQ ID NOs: 17-19 and comprises an N-terminal amino acid that is a D-amino acid.
- 12. A method of separating, isolating, purifying, characterizing, identifying, or quantifying fibrinogen in a sample, which method comprises (a) contacting a sample comprising fibrinogen with the peptide of claim 1 to form a fibrinogen-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the fibrinogen-peptide complex.
- 13. The method of claim 12, wherein the peptide is attached to a support.
- 14. The method of claim 13, wherein the support is a chromatography resin or a membrane.
- 15. The method of claim 12, wherein the peptide consists essentially of an amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 21.
- 16. A method of separating, isolating, purifying, characterizing, identifying, or quantifying fibrinogen in a sample, which method comprises (a) contacting a sample comprising fibrinogen with the peptide of claim 6 to form a fibrinogen-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the fibrinogen-peptide complex.
- 17. The method of claim 16, wherein the peptide is attached to a support.
- 18. The method of claim 17, wherein the support is a chromatography resin or a membrane.
- 19. A method of separating, isolating, purifying, characterizing, identifying, or quantifying of removing fibrinogen in a sample, which method comprises (a) contacting a sample comprising fibrinogen with the peptide of claim 10 to form a fibrinogen-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the fibrinogen-peptide complex.
- 20. The method of claim 19, wherein the peptide is attached to a support.
- 21. The method of claim 20, wherein the support is a chromatography resin or a membrane.
- 22. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Xaa8-Xaa8-Xaa1-His-Xaa1-Xaa3 (SEQ ID NO: 3), wherein
Xaa1 is hydrophobic amino acid, Xaa3 is a polar amino acid with a side chain comprising an amide, and Xaa8 is an aromatic amino acid, and wherein the peptide binds to α1 proteinase inhibitor (API) and/or a protein complex comprising paraoxonase and Apo-A1 lipoprotein.
- 23. The isolated or purified peptide of claim 22, wherein Xaa8 at position 1 is Trp, Tyr, 1-naphthylalanine (na1′), or 2-naphthylalanine (na2′), and Xaa3 at position 6 is Asn or Gln.
- 24. The isolated or purified peptide of claim 23, wherein Xaa8 at position 2 is Trp, Tyr, na1′, or na2′, Xaa1 at position 3 is Leu, and Xaa1 at position 5 is Ile.
- 25. The isolated or purified peptide of claim 22, wherein amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
- 26. A composition comprising the peptide of claim 22 and a carrier.
- 27. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence His-Xaa8-Xaa9-Xaa1-Xaa10-Xaa2 (SEQ ID NO: 4), wherein
Xaa1 is a hydrophobic amino acid, Xaa2 is a basic amino acid, Xaa8 is an aromatic amino acid, Xaa9 is an acidic amino acid or a hydrophobic amino acid, and Xaa10 is a hydrophobic amino acid or His, and wherein the peptide binds to API.
- 28. The isolated or purified peptide of claim 27, wherein the peptide consists essentially of L-amino acids.
- 29. The isolated or purified peptide of claim 27, wherein the peptide consists essentially of an amino acid sequence of SEQ ID NO: 46 or SEQ ID NO: 47.
- 30. A composition comprising the peptide of claim 27 and a carrier.
- 31. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36, 38, 39, 45, 48, 54, and 55, wherein the peptide binds to API.
- 32. The isolated or purified peptide of claim 31, wherein the amino acid sequence comprises an N-terminal amino acid that is a D-amino acid.
- 33. A composition comprising the peptide of claim 31 and a carrier.
- 34. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 59-62, wherein the peptide binds to a protein complex comprising Apo-A1 lipoprotein and paraoxonase.
- 35. A composition comprising the peptide of claim 34 and a carrier.
- 36. A method of separating, isolating, purifying, characterizing, identifying, or quantifying API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase in a sample, which method comprises (a) contacting a sample comprising API and/or a protein complex comprising Apo-A1 lipoprotein and paraoxonase with the peptide of claim 22 to form an API-peptide complex or a complex comprising the peptide and Apo-A1 lipoprotein and/or paraoxonase, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the API-peptide complex and/or the complex comprising the peptide and Apo-A1 lipoprotein and/or paraoxonase.
- 37. The method of claim 36, wherein the peptide is attached to a support.
- 38. The method of claim 37, wherein the support is a chromatography resin or a membrane.
- 39. The method of claim 36, wherein the peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 34, 39, 40, 50, 54 and 55.
- 40. A method of separating, isolating, purifying, characterizing, identifying, or quantifying API in a sample, which method comprises (a) contacting a sample comprising API with the peptide of claim 27 to form an API-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the API-peptide complex.
- 41. The method of claim 40, wherein the peptide is attached to a support.
- 42. The method of claim 41, wherein the support is a chromatography resin or a membrane.
- 43. A method of separating, isolating, purifying, characterizing, identifying, or quantifying API in a sample, which method comprises (a) contacting a sample comprising API with the peptide of claim 31 to form an API-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the API-peptide complex.
- 44. The method of claim 43, wherein the peptide is attached to a support.
- 45. The method of claim 44, wherein the support is a chromatography resin or a membrane.
- 46. A method of separating, isolating, purifying, characterizing, identifying, or quantifying a protein complex comprising Apo-A1 lipoprotein and paraoxonase in a sample, which method comprises (a) contacting a sample comprising a protein complex comprising Apo-A1 lipoprotein and paraoxonase with the peptide of claim 34 to form a complex comprising Apo-A1 lipoprotein, paraoxonase, and the peptide of claim 34, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the complex.
- 47. The method of claim 46, wherein the peptide is attached to a support.
- 48. The method of claim 47, wherein the support is a chromatography resin or a membrane.
- 49. An isolated or purified peptide comprising no more than 6 amino acids and comprising an amino acid sequence Xaa4-Xaa5-Xaa5, wherein
Xaa4 is a hydrophobic amino acid or an aromatic amino acid, and Xaa5 is an acidic amino acid, and wherein the peptide does not comprise His, Arg, or Lys, and binds to von Willebrand Factor (vWF).
- 50. The isolated or purified peptide of claim 49, wherein Xaa5 is Asp or Glu.
- 51. The isolated or purified peptide of claim 49, wherein the peptide consists essentially of an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-66, 68-73, and 111.
- 52. A composition comprising the peptide of claim 49 and a carrier.
- 53. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence Tyr-Leu-Xaa11-Xaa4-Xaa12-Thr, wherein
Xaa4 is a hydrophobic amino acid or an aromatic amino acid, Xaa11 is an aromatic amino acid or His, and Xaa12 is a hydrophobic amino acid or a polar amino acid, and wherein the peptide binds to vWF.
- 54. The isolated or purified peptide of claim 53, wherein the Xaa11 is His or Tyr, Xaa4 is Tyr or Ala, and Xaa12 is Gln or Leu.
- 55. An isolated or purified peptide comprising no more than 10 amino acids and comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 67, 76, and 77, wherein the peptide binds to vWF.
- 56. A method of separating, isolating, purifying, characterizing, identifying, or quantifying vWF in a sample, which method comprises (a) contacting a sample comprising vWF with the peptide of claim 49 to form a vWF-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the vWF-peptide complex.
- 57. The method of claim 56, wherein the peptide is attached to a support.
- 58. The method of claim 57, wherein the support is a chromatography resin or a membrane.
- 59. The method of claim 57, wherein Factor VIII is bound to vWF, and the Factor VIII is co-purified with the vWF.
- 60. A method of separating, isolating, purifying, characterizing, identifying, or quantifying vWF in a sample, which method comprises (a) contacting a sample comprising vWF with the peptide of claim 53 to form a vWF-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the vWF-peptide complex.
- 61. The method of claim 60, wherein the peptide is attached to a support.
- 62. The method of claim 61, wherein the support is a chromatography resin or a membrane.
- 63. The method of claim 61, wherein Factor VIII is bound to vWF, and the Factor VIII is co-purified with the vWF.
- 64. A method of separating, isolating, purifying, characterizing, identifying, or quantifying vWF in a sample, which method comprises (a) contacting a sample comprising vWF with the peptide of claim 55 to form a vWF-peptide complex, and (b) separating, isolating, purifying, characterizing, identifying, or quantifying the vWF-peptide complex.
- 65. The method of claim 64, wherein the peptide is attached to a support.
- 66. The method of claim 65, wherein the support is a chromatography resin or a membrane.
- 67. The method of claim 64, wherein Factor VIII is bound to vWF, and the Factor VIII is co-purified with the vWF.
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
[0001] This patent application claims the benefit of U.S. Provisional Patent Application No. 60/372,091, filed Apr. 15, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60372091 |
Apr 2002 |
US |